

or (ii) that compound or its pharmaceutically acceptable salt or ester or (iii) pharmaceutical compositions containing those compounds. The claims also cover methods for the treatment of post-angioplasty restenosis, cardiovascular disease, and inflammatory disorders that include administering an effective amount of these compounds. None of the claims are of exactly the same claim scope as the claims in either U.S. Patent No. 6,147,250 or 6,121,319. A terminal disclaimer is submitted herewith, disclaiming the terminal portion of any patent that issues on the above application that would extend beyond the term of either U.S. Patent No. 6,121,319, or U.S. Pat. No. 6,147,250.

Information Disclosure Statement

The Office Action indicates that references BC and BF previously submitted in this application were not considered because they failed to comply with 37 CFR 1.98(a)(2). Included herewith is a Supplemental Information Disclosure Statement that includes English language abstracts of these references.

The Office Action further indicates that reference CA was not considered because Applicants did not comply with 37 CFR 1.98(a)(3). However, because reference CA is not a foreign language reference, Applicant submits that there is no need to comply with 37 CFR 1.98(a)(3). Enclosed is another copy of reference CA for the Examiner's convenience.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance and earnestly solicits a prompt allowance of all pending claims. Should the Examiner have any questions about this application he is invited to contact the undersigned at 404-572-3541.

Applicants owe the Patent Office $2,802.00 for this submission and the related submissions enclosed herewith (11 extra independent claims ($924.00), 66 extra total claims

($1,188.00), two month extension (400.00), IDS fee ($180.00), and terminal disclaimer fee ($110.00)). Enclosed is a check in the amount of $1,500.00 to partially cover these fees. The Commissioner is authorized to charge the remaining $1,302.00, and further to charge any additional fee or credit any overpayment associated with this submission, to Deposit Account No. 11-0980

Respectfully submitted,

Sherry M. Knowles
Registration No. 33,052

King & Spalding
191 Peachtree Street
Atlanta, Georgia 30303
Telephone: 404-572-3478
Facsimile: 404-572-5145

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Amendment and Response to Office Action, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: November 30, 2001

REPLACEMENT CLAIM SET

13) A compound of the formula:



14) A compound of the formula



or a pharmaceutically acceptable salt or ester thereof.

15) A pharmaceutical composition comprising an effective treatment amount of the compound of the formula:



together with a pharmaceutically acceptable carrier.

16) A pharmaceutical composition comprising an effective treatment amount of a compound of the formula:



or a pharmaceutically acceptable salt or ester thereof, together with a pharmaceutically acceptable carrier.

17) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for oral administration.

18) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for topical administration.

19) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

20) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous administration.

21) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for intraperitoneal administration.

22) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for intramuscular administration.

23) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for submucosal administration.

24) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for inhalation administration.

25) The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable carrier is suitable for transdermal administration.

26) A method for the treatment of post-angioplasty restenosis comprising administering an effective treatment amount to a host in need thereof of the compound of the formula:



optionally in a pharmaceutically acceptable carrier.

27) A method for the treatment of post-angioplasty restenosis comprising administering an effective treatment amount to a host in need thereof of a compound of the formula:



or a pharmaceutically acceptable salt or ester thereof, optionally in a pharmaceutically acceptable carrier.

28) A method for the treatment of a cardiovascular disorder comprising administering an effective treatment amount to a host in need thereof of the compound of the formula:



optionally together with a pharmaceutically acceptable carrier.

29) A method for the treatment of a cardiovascular disorder comprising administering an effective treatment amount to a host in need thereof of a compound of the formula:



or a pharmaceutically acceptable salt or ester thereof, optionally together with a pharmaceutically acceptable carrier.

30) A method for treating a host prior to coronary angioplasty comprising administering an effective treatment amount of the compound of the formula



optionally together with a pharmaceutically acceptable carrier.

31) A method of treating a host prior to coronary angioplasty comprising administering an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt or ester thereof, optionally together with a pharmaceutically acceptable carrier.

32) A method for treating a host with coronary artery disease lesions comprising administering an effective treatment amount of the compound of the formula



optionally together with a pharmaceutically acceptable carrier.

33) A method of treating a host with coronary artery disease lesions comprising administering an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt or ester thereof, optionally together with a pharmaceutically acceptable carrier.

34) A method for the treatment of an inflammatory disorder comprising administering an effective treatment amount to a host in need thereof of the compound of the formula



optionally together with a pharmaceutically acceptable carrier.

35) A method for the treatment of an inflammatory disorder comprising administering an effective treatment amount to a host in need thereof of a compound of the formula



or a pharmaceutically acceptable salt or ester thereof, optionally together with a pharmaceutically acceptable carrier.

36) The method of claim 27, wherein the administration is by oral administration.

37) The method of claim 29, wherein the administration is by oral administration.

38) The method of claim 31, wherein the administration is by oral administration.

39) The method of claim 33, wherein the administration is by oral administration.

40) The method of claim 35, wherein the administration is by oral administration.

41) The method of claim 27, wherein the administration is by topical administration.

42) The method of claim 29, wherein the administration is by topical administration.

43) The method of claim 31, wherein the administration is by topical administration.

44) The method of claim 33, wherein the administration is by topical administration.

45) The method of claim 35, wherein the administration is by topical administration.

46) The method of claim 27, wherein the administration is by intravenous administration.

47) The method of claim 29, wherein the administration is by intravenous administration.

48) The method of claim 31, wherein the administration is by intravenous administration.

49) The method of claim 33, wherein the administration is by intravenous administration.

50) The method of claim 35, wherein the administration is by intravenous administration.

51) The method of claim 27, wherein the administration is by subcutaneous administration.

52) The method of claim 29, wherein the administration is by subcutaneous administration.

53) The method of claim 31, wherein the administration is by subcutaneous administration.

54) The method of claim 33, wherein the administration is by subcutaneous administration.

55) The method of claim 35, wherein the administration is by subcutaneous administration.

56) The method of claim 27, wherein the administration is by intraperitoneal administration.

57) The method of claim 29, wherein the administration is by intraperitoneal administration.

58) The method of claim 31, wherein the administration is by intraperitoneal administration.

59) The method of claim 33, wherein the administration is by intraperitoneal administration.

60) The method of claim 35, wherein the administration is by intraperitoneal administration.

61) The method of claim 27, wherein the administration is by intramuscular administration.

62) The method of claim 29, wherein the administration is by intramuscular administration.

63) The method of claim 31, wherein the administration is by intramuscular administration.

64) The method of claim 33, wherein the administration is by intramuscular administration.

65) The method of claim 35, wherein the administration is by intramuscular administration.

66) The method of claim 27, wherein the administration is by submucosal administration.

67) The method of claim 29, wherein the administration is by submucosal administration.

68) The method of claim 31, wherein the administration is by submucosal administration.

69) The method of claim 33, wherein the administration is by submucosal administration.

70) The method of claim 35, wherein the administration is by submucosal administration.

71) The method of claim 27, wherein the administration is by inhalation administration.

72) The method of claim 29, wherein the administration is by inhalation administration.

73) The method of claim 31, wherein the administration is by inhalation administration.

74) The method of claim 33, wherein the administration is by inhalation administration.

75) The method of claim 35, wherein the administration is by inhalation administration.

76) The method of claim 27, wherein the administration is by transdermal administration.

77) The method of claim 29, wherein the administration is by transdermal administration.

78) The method of claim 31, wherein the administration is by transdermal administration.

79) The method of claim 33, wherein the administration is by transdermal administration.

80) The method of claim 35, wherein the administration is by transdermal administration.

81) The method of claim 29, wherein the cardiovascular disorder is atherosclerosis.

82) The method of claim 29, wherein the cardiovascular disorder is coronary artery disease.

83) The method of claim 29, wherein the cardiovascular disorder is angina.

84) The method of claim 29, wherein the cardiovascular disorder is small artery disease.

85) The method of claim 35, wherein the inflammatory disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, dermatitis, multiple sclerosis and psoriasis.

86) The method of claim 29, further comprising administering the compound in combination with one or more cardiovascular drugs.

87) The method of claim 86 wherein the cardiovascular drug is selected from the group consisting of lipid lowering agents, platelet aggregation inhibitors, antithrombotic agents, calcium channel blockers, angiotensin convening enzyme (ACE) inhibitors, and β-blockers.

88) The method of claim 35, further comprising administering the compound in combination with one or more antiinflammatory drugs.

89) The method of claim 88 wherein the antiinflammatory drug is selected from the group consisting of ibuprofen, indomethacin, fenoprofen, mefenaminacid, flufenamic acid, sulindac, and corticosteriods.

90) The method of claim 26 wherein the host is a human.

91) The method of claim 27 wherein the host is a human.

92) The method of claim 28 wherein the host is a human.

93) The method of claim 29 wherein the host is a human.

94) The method of claim 30 wherein the host is a human.

95) The method of claim 31 wherein the host is a human.

96) The method of claim 32 wherein the host is a human.

97) The method of claim 33 wherein the host is a human.

98) The method of claim 34 wherein the host is a human.

99) The method of claim 35 wherein the host is a human.

Version with Markings to Show Changes Made

In the claims

Claims 1-12 have been canceled.

Claims 13-99 have been added as indicated in the Replacement Claim Set.